The funding will allow Deep 6 AI to better meet the demand of healthcare provider, pharmaceutical company and research organization clients for its suite of clinical trial-optimizing AI tools. The startup will also further refine those tools and expand its network of clients, which currently includes Cedars-Sinai Medical Center in Los Angeles and Houston-based Texas Medical Center, among several other health systems, life sciences companies, devicemakers and research facilities.
The Pasadena, Calif.-based company, which was founded in 2015, is an alumnus of several accelerator programs, including Texas Medical Center’s TMCx in early 2018 and Stanford (Calif.) University’s now-defunct StartX in the fall of 2016, the latter of which provided Deep 6 AI with approximately $600,000 in seed funding and other resources.
More articles on AI:
Human-AI collaboration more effective than either working alone: Stanford study
AI predicts seizures 1 hour before onset with 99.6% accuracy, study finds
Novartis launches program with Biofourmis for AI monitoring of heart failure patients
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
